-Patients treated at the high dose show impressive survival benefit–IL4R population surviving twice as long as current approved treatments- TORONTO and HOUSTON, Sept 25, 2019 /PRNewswire/ – Medicenna Therapeutics Corp. (“Medicenna” or...
Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with vitiligo. “The...
Medtronic Continues to Invest in Scientific Evidence for Expansion of Indications and Greater Clinical Understanding of Infuse™ Bone Graft Medtronic plc (NYSE:MDT) today announced U.S. FDA approval of a prospective, randomized pivotal clinical trial for the use of...
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces it has enrolled 158 patients in its Phase 2 trial of AG013 for the treatment of severe oral...
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its clinical activities. The Company reported that it is on track to complete its Clinical...
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced completion of subject enrollment in its Phase 2 clinical trial of NSI-566 for the treatment of chronic ischemic stroke. NSI-566 is...
Email
Text